Wenhong Shen
Suzhou, 215006, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia.
Journal: Experimental hematology & oncology
Published: June 27, 2022
Blast phase of chronic myeloid leukemia with concurrent BCR::ABL1 and SET::NUP214: A report of two cases.
Journal: Molecular carcinogenesis
Published: June 22, 2022
TNF-α increases the risk of bleeding in patients after CAR T-cell therapy: A bleeding model based on a real-world study of Chinese CAR T Working Party.
Journal: Hematological oncology
Published: July 16, 2021
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Journal: Journal of hematology & oncology
Published: February 06, 2021
HLA-DQB1 mismatch increase risk of severe bleeding independently in recipients of allogeneic stem cell transplant.
Journal: Annals of hematology
Published: September 08, 2020
Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.
Journal: American journal of cancer research
Published: August 10, 2018
First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.
Journal: American journal of cancer research
Published: April 30, 2018
Clinical significance of circulating microparticles in Ph- myeloproliferative neoplasms.
Journal: Oncology letters
Published: November 07, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026